These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11242510)

  • 1. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis.
    Vlahakos DV; Marathias KP; Kosmas EN
    Ann Intern Med; 2001 Mar; 134(5):426-7. PubMed ID: 11242510
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease.
    Vlahakos DV; Kosmas EN; Dimopoulou I; Ikonomou E; Jullien G; Vassilakos P; Marathias KP
    Am J Med; 1999 Feb; 106(2):158-64. PubMed ID: 10230744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of theophylline on erythrocytosis in chronic obstructive pulmonary disease.
    Oren R; Beeri M; Hubert A; Kramer MR; Matzner Y
    Arch Intern Med; 1997 Jul; 157(13):1474-8. PubMed ID: 9224226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis.
    Tsang WK; Tong KL; Chan HW
    Transplant Proc; 1998 Nov; 30(7):3072-3. PubMed ID: 9838354
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of losartan on posttransplant erythrocytosis.
    Colak T; Emiroglu R; Karakayali H; Haberal M
    Transplant Proc; 2001; 33(1-2):2014-5. PubMed ID: 11267606
    [No Abstract]   [Full Text] [Related]  

  • 6. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
    Julian BA; Brantley RR; Barker CV; Stopka T; Gaston RS; Curtis JJ; Lee JY; Prchal JT
    J Am Soc Nephrol; 1998 Jun; 9(6):1104-8. PubMed ID: 9621296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of losartan on the treatment of posttransplant erythrocytosis.
    Navarro JF; García J; Macía M; Mora C; Chahin J; Gallego E; Méndez ML; del Castillo N
    Clin Nephrol; 1998 Jun; 49(6):370-2. PubMed ID: 9696433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.
    Hortal L; Fernández A; Vega N; Rodríguez JC; Losada A; Lorenzo M; Plaza C; Palop L
    Transplant Proc; 1998 Aug; 30(5):2127-8. PubMed ID: 9723415
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis.
    Iñigo P; Torregrosa JV; Campistol JM; Oppenheimer F
    Transplant Proc; 1999 Sep; 31(6):2321. PubMed ID: 10500598
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of theophylline to control hematocrit in respiratory polycythemia.
    Souweine B; Serre AF; Fialip J; Jimenez C; Philippe P
    Ann Pharmacother; 1993; 27(7-8):978. PubMed ID: 8364287
    [No Abstract]   [Full Text] [Related]  

  • 11. Bloodletting and exchange transfusion with Dextran 40 in polycythemia secondary to chronic obstructive lung disease.
    Schaanning J; Sparr S
    Scand J Respir Dis; 1974; 55(4):237-44. PubMed ID: 4438984
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF.
    Stoll ML; Gauthier BG; Vergara M; Ramek J; Frank R; Trachtman H
    Pediatr Nephrol; 2004 Jan; 19(1):120-1. PubMed ID: 14634866
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful long-term treatment of post-transplant erythrocytosis with losartan.
    Midtvedt K; Stokke ES; Hartmann A
    Nephrol Dial Transplant; 1996 Dec; 11(12):2495-7. PubMed ID: 9017632
    [No Abstract]   [Full Text] [Related]  

  • 14. Isovolemic hemodilution in erythrocytosis secondary to chronic obstructive lung disease.
    Danielson M; Nordenström J
    Acta Med Scand; 1979; 206(4):327-32. PubMed ID: 506807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic beneficial effects of type 1 angiotensin II receptor antagonist in patients with chronic hypoxemic pulmonary diseases.
    Ogawa M; Hirose N; Ogimoto M; Matsuki H; Miki K; Kinoshita M; Koga A; Saku K
    Cardiology; 2002; 97(2):111-2. PubMed ID: 11978959
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
    Morale W; Puliatti C; Veroux P; Veroux M; Valvo C; Cappello D; Puliatti D; Francesco L
    Minerva Urol Nefrol; 2002 Jun; 54(2):145-8. PubMed ID: 12070465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan for therapy of posttransplant erythrocytosis.
    Navarro JF; Macía M; García J
    Clin Nephrol; 1997 Nov; 48(5):335. PubMed ID: 9403221
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of secondary polycythemia on cerebral blood flow in chronic obstructive pulmonary disease.
    York EL; Jones RL; Menon D; Sproule BJ
    Am Rev Respir Dis; 1980 May; 121(5):813-8. PubMed ID: 7406315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and clinical efficiency of long-term complete blockade of renin-angiotensin-aldosterone system in patients with chronic obstructive pulmonary diseases].
    Arutiunov GP; Korsunskaia MI; Cherniavskaia TK; Vershinin AA; Rozanov AV; Balanina NO
    Ter Arkh; 2000; 72(10):52-6. PubMed ID: 11220879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia in chronic obstructive pulmonary disease. A study of serum and urine erythropoietin and medullary erythroid progenitors.
    Guidet B; Offenstadt G; Boffa G; Najman A; Baillou C; Hatzfeld C; Amstutz P
    Chest; 1987 Nov; 92(5):867-70. PubMed ID: 3665602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.